Missed functional drink deal, now a NCC deal that was to happen by year end. Strike 2.

I could never figure it out, if CZO was on the cusp of something great, such as a commerical deal to validate application(s) of PGX (or even a COVID therapeutic) why haven't insiders been buying shares?

Just by human nature, the tendency would be to greatly benefit (not greed) from the fruits of their labour working at Ceapro. Are they all waiting for a deal before buying in?

Since a deal was dangled in front of investors and considering how important a deal would be for the share price, this is a material event that did not occur, as such regulatory requirements would require a news release from the company.

This is no different than a company saying we will have a deal for X with an unnamed company by the end of the year.